Novo Nordisk · 8 hours ago
Internship - Commercial Sales Execution - West Area
Plainsboro, NJ, US
Internship
Onsite
InternNovo Nordisk is a global pharmaceutical company focused on cardiometabolic care. The intern will work with the West Area Commercial Execution team, engaging in various business areas such as Field Sales Support and Data Analysis, while delivering insights and action plans to senior leadership.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Evaluating the efficiency and impact of key initiatives across the Area
Collaborate closely with senior leadership, people leaders, and other key stakeholders
Leveraging tools such as Tellius and CONNEX to identify trends, gaps, and opportunities
Deliver solution-oriented insights and a practical action plan presented to the Area Commercial Lead and the Director of Commercial Execution for the assigned focus area
Qualification
Required
Must be a current student enrolled or recently graduated (graduation date no earlier than April 2026) at/from an accredited college or university pursuing at least a bachelor's degree
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
A completed or in progress undergraduate degree in Business Administration, Marketing or a related discipline preferred
Class year of a junior or senior preferred
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
Labiotech UG
2026-01-24
bloomberglaw.com
2026-01-24
Company data provided by crunchbase